OMER - Omeros Corporation
| Previous Close | 13.95 |
| Open | 13.96 |
| Bid | 13.990 x 800 |
| Ask | 14.030 x 800 |
| Day's Range | 13.95 - 14.10 |
| 52 Week Range | 8.36 - 27.00 |
| Volume | 26,208 |
| Avg. Volume | 629,251 |
| Market Cap | 689.561M |
| Beta (3Y Monthly) | 3.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.478 |
| Earnings Date | Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.25 |
- GlobeNewswire•2 hours ago
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 days ago
Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
Omeros Corporation today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.” Narsoplimab is the company’s lead human monoclonal antibody targeting mannan-binding ...
- Motley Fool•8 days ago
Why Omeros Stock Jumped Today
The small biotech received good news from the FDA.
- Business Wire•8 days ago
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Omeros Corporation (OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the required work and further advanced its preparations for its Biologics License Application (BLA) for OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is the company’s Phase 3 human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
- Business Wire•10 days ago
Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
Omeros Corporation (OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company.
- Simply Wall St.•23 days ago
Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register?
A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
- Benzinga•last month
Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data
IgA nephropathy is a kidney disease resulting from the accumulation of an antibody called immunoglobin A in the kidney, which causes inflammation and in turn impacts the ability of the kidney to filter wastes from blood. Following a meeting with the FDA on the Phase 3 trial, Omeros said Thursday it has finalized its clinical plan for OMS721. The company said the FDA agreed to extend the primary endpoint of the assessment of proteinuria from 24 weeks to 36 weeks to allow additional dosing if warranted.
- Business Wire•last month
Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
Omeros Corporation (OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. There is no approved treatment for IgA nephropathy.
- Business Wire•last month
Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
Omeros Corporation (OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018. Omeros’ preliminary (unaudited) total and OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% revenues for the fourth quarter of 2018 are expected to be a record high at approximately $22.0 million compared to $4.6 million in 3Q 2018 and $13.8 million in the prior year fourth quarter. The increase from the prior periods reflects strong demand for OMIDRIA from ambulatory surgery centers (ASCs) and hospitals following reinstatement of pass-through reimbursement for OMIDRIA on October 1, 2018.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•2 months ago
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
Omeros Corporation (OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy. The committee includes renowned leaders in nephrology and clinical research who will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
- Business Wire•2 months ago
Omeros Announces Research Collaboration with University of Cambridge
Omeros Corporation (OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.
- Business Wire•3 months ago
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –
- Business Wire•3 months ago
Omeros Announces Additions to Senior Management Team
Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Omeros Corp Earnings Call
- Simply Wall St.•3 months ago
Does Omeros Corporation’s (NASDAQ:OMER) CEO Salary Reflect Performance?
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
- Motley Fool•3 months ago
Here's Why Omeros Corporation Fell as Much as 24.5% Today
The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.
- Benzinga•3 months ago
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
- Business Wire•3 months ago
Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
Omeros Corporation (OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Omeros has granted the initial purchasers of the Notes an option to purchase up to an additional $40 million aggregate principal amount of the Notes on the same terms and conditions referenced above. The Notes will be senior unsecured obligations of Omeros and interest will be payable semi-annually in arrears at a rate of 6.25% per annum.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...
- Zacks•3 months ago
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Omeros: 3Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had a loss of 81 cents. Losses, adjusted for non-recurring costs, were 71 cents per share. The drug developer posted revenue of $4.6 million in the ...
- PR Newswire•3 months ago
Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Securities Act"). Omeros also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $40 million aggregate principal amount of the Notes, for a total potential offering size of $250 million. The Notes will mature on November 15, 2023, unless earlier converted, repurchased or redeemed in accordance with their terms, and will be convertible, subject to the satisfaction of certain conditions, into cash, shares of Omeros' common stock or a combination thereof as elected by Omeros in its sole discretion.
- Business Wire•3 months ago
Omeros Corporation Reports Third Quarter 2018 Financial Results
– Conference Call Friday, November 9th at 8:30 a.m. ET –
